Research methods
Preclinical data vs human evidence
Why preclinical (animal and in vitro) data does not establish human safety or efficacy, and why this distinction matters when reading peptide research.
Animal and cell-culture data inform hypothesis generation, mechanism, and dose-range selection. They do not establish human safety or efficacy.
Translation rates are humbling
Across pharmacology, the historical rate at which compounds with promising preclinical data become licensed medicines is low (~10% from phase 1, lower from preclinical). Receptor selectivity in vitro does not predict integrated clinical outcome.
Mechanistic plausibility vs outcome evidence
A plausible mechanism is necessary but not sufficient. The literature is full of mechanistically plausible compounds that did not translate into clinical benefit, and the reverse — compounds whose clinical benefit is real but whose mechanism is still debated.
Implications for research-only peptides
Compounds like AOD-9604 and HGH Fragment 176-191 have intriguing preclinical and animal data but limited and old human evidence. They are research-only because that translation has not happened, not because translation is around the corner.
Key takeaways
- Preclinical data is hypothesis-shaping, not outcome-deciding.
- Mechanistic plausibility is not clinical benefit.
- Research-only compounds should be discussed at their actual evidence stage.
- Formal statistical training.
- Individual treatment, prescribing or dosing advice.
- Permission to skip the original publication of any trial cited.